Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results
Rhea-AI Summary
Senseonics (NASDAQ: SENS) reported Q1 2026 revenue of $11.7M, up 87% YoY, and gross profit of $6.9M with a 59% gross margin. The company raised over $100M in equity and debt, launched Eversense 365 in Europe, and updated full‑year 2026 revenue guidance to $60M–$64M with expected gross margins of 55%–58%.
Positive
- Revenue +87% YoY to $11.7M in Q1 2026
- Raised over $100M in combined equity and debt financing
- Updated FY2026 revenue guidance to $60M–$64M
- Q1 gross margin of 59%, up 35% YoY
Negative
- Net loss widened to $32.3M in Q1 2026 from $14.3M
- SG&A increased by $22.5M YoY to $30.2M in Q1
- R&D spend rose by $1.3M YoY to $8.6M in Q1
News Market Reaction – SENS
In the May 8 session, SENS declined 6.16%, reflecting a notable negative market reaction. Argus tracked a peak move of +3.7% during that session. Argus tracked a trough of -14.1% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility. Trading volume was very high at 4.5x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Q4/FY 2025 earnings | Positive | -18.1% | Strong Q4 and FY 2025 revenue growth and higher 2026 guidance. |
| Nov 05 | Q3 2025 earnings | Positive | -7.6% | Q3 2025 revenue up 90% YoY and gross profit improvement. |
| Aug 06 | Q2 2025 earnings | Positive | -4.9% | Q2 2025 revenue growth and bolstered capital via offerings. |
| May 08 | Q1 2025 earnings | Positive | -15.2% | Q1 2025 revenue growth and improved gross profit with guidance. |
| Mar 03 | Q4/FY 2024 earnings | Positive | -19.3% | Q4 and FY 2024 growth plus US launch of Eversense 365 CGM. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases have frequently been followed by negative price reactions, despite strong growth metrics, indicating a history of post-earnings weakness.
Over the past year, Senseonics has repeatedly reported strong revenue growth and product milestones, particularly around Eversense 365, yet its earnings releases have often been followed by share price declines. The last five earnings-related announcements (from Mar 03, 2025 through Mar 02, 2026) all saw negative next-day moves despite higher revenues, improving gross margins, and expanding guidance. Today’s Q1 2026 report, with raised full-year revenue and margin outlook, continues this operational momentum.
Key Terms
continuous glucose monitoring medical
automated insulin delivery medical
ce mark regulatory
pre-funded warrants financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Generated Q1 revenue of
Expect full-year revenue in the range of
Strong strategic and commercial progress, including the launch of Eversense® 365 in Europe
Raised
GERMANTOWN, MD., May 07, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced first quarter 2026 financial results and provided a business update.
Recent Highlights & Accomplishments
- Generated Q1 revenue of
$11.7 million , an increase of87% year-over-year - Continued commercial momentum for Eversense 365 in the US, primarily driven by direct-to-consumer marketing efforts, with DTC new patient adds up nearly
100% year-over-year. - Achieved gross margin of
59% in Q1, an increase of35% year-over-year, reflecting benefits from the commercial transition, scale and manufacturing efficiencies - Initiated commercial launch with twiist™ to support US patient growth, with encouraging early uptake of Eversense 365 as part of an Automated Insulin Delivery (AID) system
- Currently launching Eversense 365 in Europe with first insertions in Sweden in April, following CE Mark approval in January
- Raised
$92 million in growth capital through recent public offering of securities - Amended and expanded Hercules debt facility to further strengthen balance sheet
Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics, said, “This was our first quarter as a fully-integrated commercial organization in the U.S., following the successful transition of the U.S. Eversense Sales and Marketing team to Senseonics. However, this wasn’t just a quarter of important strategic progress, it was a strong quarter of commercial delivery, with both revenue and gross margins exceeding our expectations. We have now secured over
First Quarter 2026 Results:
Total revenue for the first quarter of 2026 was
First quarter 2026 gross profit was
First quarter 2026 research and development expenses increased by
First quarter 2026 selling, general and administrative expenses increased by
Net loss was
Cash, cash equivalents and investments were
Full Year 2026 Financial Outlook
Senseonics now expects full-year 2026 global net revenue to be approximately
Conference Call Information
Management will hold a conference call to review the Company’s first quarter 2026 performance starting today at 4:30 p.m. (Eastern Time). The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics’ website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-800-225-9448 (US/Canada) or 1-203-518-9708 (International), passcode SENSQ1, approximately five to ten minutes prior to start time.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see https://www.eversensediabetes.com/safety-info/.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for Senseonics, including the revenue and gross margin projections under the heading “Full Year 2026 Financial Outlook,” statements regarding the ongoing transition of Eversense commercial operations from Ascensia, the commercial launch of Eversense 365 in Europe, the continued investment in the commercialization of Eversense 365 in the U.S. and Europe, the Company’s product development pipeline including Gemini and Freedom, the expanded compatibility of Eversense 365 with automated insulin delivery systems and the future demand for Eversense, and other statements containing the words "believe," “expect,” “intend,” “may,” “projects,” “will,” “planned,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks and uncertainties related to the transition of commercial activities from Ascensia and the establishment of Senseonics’ capabilities and processes in Europe, uncertainties in insurer, regulatory and administrative processes and decisions and the finalization of new product version technology upgrades for European tenders and other customers, uncertainties in the development, registration and roll-out of new technology and solutions, uncertainties inherent in the ongoing commercialization of the Eversense product, the expansion of the Eversense product and Senseonics’ and its partners’ activities, uncertainties relating to the ability satisfy conditions for funding of future tranches of borrowing under the amended credit facility with Hercules, uncertainties relating to the availability and terms of future financing, uncertainties relating to the current economic and regulatory/political environment, including the effects of tariffs, and such other factors as are set forth in the risk factors detailed in Senseonics' Annual Report on Form 10-K for the year ended December 31, 2025 and quarterly reports on Form 10-Q filed with the SEC under the heading "Risk Factors." The forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
| Senseonics Holdings, Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) | ||||||||
| March 31, | December 31, | |||||||
| 2026 | 2025 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 29,612 | $ | 40,234 | ||||
| Restricted cash | 315 | 315 | ||||||
| Short term investments, net | 34,709 | 53,796 | ||||||
| Accounts receivable, net | 10,655 | 6,807 | ||||||
| Accounts receivable, net - related parties | 4,056 | 5,312 | ||||||
| Inventory, net | 8,308 | 6,703 | ||||||
| Prepaid expenses and other current assets | 4,626 | 4,366 | ||||||
| Total current assets | 92,281 | 117,533 | ||||||
| Deposits and other assets | 6,429 | 4,536 | ||||||
| Property, equipment and intangible assets, net | 4,147 | 4,200 | ||||||
| Total assets | $ | 102,857 | $ | 126,269 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,188 | $ | 4,059 | ||||
| Accrued expenses and other current liabilities | 15,097 | 15,091 | ||||||
| Accrued expenses and other current liabilities, related parties | 8,040 | 5,198 | ||||||
| Total current liabilities | 26,325 | 24,348 | ||||||
| Long-term debt and notes payables, net | 35,912 | 35,586 | ||||||
| Non-current operating lease liabilities | 6,285 | 5,289 | ||||||
| Total liabilities | 68,522 | 65,223 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Common stock, | 42 | 41 | ||||||
| Additional paid-in capital | 1,083,605 | 1,077,923 | ||||||
| Accumulated other comprehensive income | 8 | 69 | ||||||
| Accumulated deficit | (1,049,320 | ) | (1,016,987 | ) | ||||
| Total stockholders’ equity | 34,335 | 61,046 | ||||||
| Total liabilities and stockholders’ equity | $ | 102,857 | $ | 126,269 | ||||
| Senseonics Holdings, Inc. Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) | ||||||||
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2026 | 2025 | |||||||
| Revenue, net | $ | 9,341 | $ | 1,810 | ||||
| Revenue, net - related parties | 2,370 | 4,447 | ||||||
| Total revenue | 11,711 | 6,257 | ||||||
| Cost of sales | 4,771 | 4,752 | ||||||
| Gross profit | 6,940 | 1,505 | ||||||
| Expenses: | ||||||||
| Research and development expenses | 8,611 | 7,299 | ||||||
| Selling, general and administrative expenses | 30,175 | 7,694 | ||||||
| Operating loss | (31,846 | ) | (13,488 | ) | ||||
| Other income (expense), net: | ||||||||
| Interest income | 742 | 675 | ||||||
| Interest expense | (1,192 | ) | (1,429 | ) | ||||
| Other expense | (37 | ) | (17 | ) | ||||
| Total other income (expense), net | (487 | ) | (771 | ) | ||||
| Net Loss | (32,333 | ) | (14,259 | ) | ||||
| Other comprehensive loss | ||||||||
| Unrealized loss on marketable securities | (61 | ) | (3 | ) | ||||
| Other comprehensive loss | (61 | ) | (3 | ) | ||||
| Total comprehensive loss | $ | (32,394 | ) | $ | (14,262 | ) | ||
| Basic net loss per common share | $ | (0.71 | ) | $ | (0.40 | ) | ||
| Basic weighted-average shares outstanding | 45,822,486 | 35,943,880 | ||||||
| Diluted net loss per common share | $ | (0.71 | ) | $ | (0.40 | ) | ||
| Diluted weighted-average shares outstanding | 45,822,486 | 35,943,880 | ||||||
